|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Cause | 1st lineN = 106 | 2nd/3rd lineN = 17 | Fisher’s exact p-value | IV-ETO 1st lineN = 58 | Oral-ETO1st lineN = 48 | Fisher’s exact p-value |
| Treatment plan completion | 44 (41.5%) | 7 (41.2%) |  | 27 (46.5%) | 17 (35.4%) |  |
| Toxicity | 16 (15.1%) | 2 (11.8%) | 1.000 | 7 (12.1%) | 9 (18.7%) | 0.418 |
| Patient decision | 12 (11.3%) | 1 (5.9%) |  | 9 (15.5%) | 3 (6.2%) |  |
| Deterioration in general condition/clinical progression | 25 (23.6%) | 6 (37.3%) |  | 11 (19.0%) | 14 (29.2%) |  |
| Death  | 9 (8.5%) | 1 (5.9%) |  | 4 (6.9%) | 5 (10.4%) |  |

**Supplementary Table S2\_Causes of discontinuation of CarboEtop**

CarboEtop = carboplatin/etoposide chemotherapy; N = number of courses of carboplatin/etoposide chemotherapy; ETO = etoposide; IV = intravenous